Challenges for gene therapy of CNS disorders and implications for parkinson's disease therapies

Human Gene Therapy

Volumn 23, Issue 4, 2011, Pages 340-343

  Broadstock, Martin ^a   Yáñez Muñoz, Rafael J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DECARBOXYLASE; CERE 120; GLUTAMATE DECARBOXYLASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; NEURTURIN; PARVOVIRUS VECTOR; PROSAVIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; NONHUMAN; NOTE; PARKINSON DISEASE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BRAIN; DEPENDOVIRUS; FEMALE; GENETIC VECTORS; HUMANS; MALE; PARKINSON DISEASE; TRANSDUCTION, GENETIC;

EID: 84860213812     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.2507     Document Type: Note

References (34)

1. Asokan, A., Schaffer, D. V., and Samulski, R. J. (2012). The AAV vector toolkit: Poised at the clinical crossroads. Mol. Ther. (in press).
2. Bell, C. L., Vandenberghe, L. H., Bell, P., et al. (2011). The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin. Invest. 121, 2427-2435.
3. Boutin, S., Monteilhet, V., Veron, P., et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704-712.
4. Calcedo, R., Morizono, H., Wang, L., et al. (2011). Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccine Immunol. 18, 1586-1588.
5. Christine, C. W., Starr, P. A., Larson, P. S., et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662-1669.
6. Diederich, N. J., and Goetz, C. G. (2008). The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology 71, 677-684.
7. Drinkut, A., Tereshchenko, Y., Schulz, J. B., et al. (2011). Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol. Ther. 20, 534-543.
8. Duque, S., Joussemet, B., Riviere, C., et al. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17, 1187-1196.
9. Federici, T., Taub, J. S., Baum, G. R., et al. (2011). Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. (in press).
10. Forsayeth, J. R., and Bankiewicz, K. S. (2011). AAV9: Over the fence and into the woods. Mol. Ther. 19, 1006-1007.
11. Foust, K. D., Nurre, E., Montgomery, C. L., et al. (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65.
12. Goetz, C. G., Wuu, J., McDermott, M. P., et al. (2008). Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Mov. Disord. 23, 690-699.
13. Gray, S. J., Blake, B. L., Criswell, H. E., et al. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570-578.
14. Gray, S. J., Foti, S. B., Schwartz, J. W., et al. (2011a). Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 22, 1143-1153.
15. Gray, S. J., Matagne, V., Bachaboina, L., et al. (2011b). Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058-1069.
16. Ichinose, H., Ohye, T., Fujita, K., et al. (1994). Quantification of mRNA of tyrosine hydroxylase and aromatic l-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J. Neural Transm. Park. Dis. Dement. 8, 149-158.
17. Jellinger, K. A. (2012). Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts. Mov. Disord 27, 8-30.
18. Kugler, S., Lingor, P., Scholl, U., et al. (2003). Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 311, 89-95. (Pubitemid 36794213)
19. LeWitt, P. A., Rezai, A. R., Leehey, M. A., et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: A doubleblind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309-319.
20. Manfredsson, F. P., Rising, A. C., and Mandel, R. J. (2009). AAV9: A potential blood-brain barrier buster. Mol. Ther. 17, 403-405.
21. Manno, C. S., Pierce, G. F., Arruda, V. R., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347. (Pubitemid 43355084)
22. Marks, W. J., Jr., Ostrem, J. L., Verhagen, L, et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol. 7, 400-408.
23. Marks WJ, Jr., Bartus RT, Siffert J, et al. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164-1172.
24. Martinez-Martin, P. (2011). The importance of non-motor disturbances to quality of life in Parkinson's disease. J. Neurol. Sci. 310, 12-16.
25. Mattar, C. N., Waddington, S. N., Biswas, A., et al. (2012). Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Ther. (in press).
26. McCown, T. J. (2011). Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 11, 181-188.
27. Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., et al. (2012). Long-term evaluation of a phase I study of AADC gene therapy for Parkinson's disease. Hum. Gene Ther. (this issue).
28. Obeso, J. A., Olanow, C. W., and Nutt, J. G. (2000). Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23, S2-S7.
29. Pulicherla, N., Shen, S., Yadav, S., et al. (2011). Engineering liverdetargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther. 19, 1070-1078.
30. Samaranch, L., Salegio, E. A., San Sebastian, W., et al. (2012). AAV9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. (this issue).
31. Shen, S., Bryant, K. D., Brown, S. M., et al. (2011). Terminal Nlinked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286, 13532-13540.
32. Witt, J., and Marks, W. J., Jr. (2011). An update on gene therapy in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 11, 362-370.
33. Xie, J., Xie, Q., Zhang, H., et al. (2011). MicroRNA-regulated, systemically delivered rAAV9: A step closer to CNS-restricted transgene expression. Mol. Ther. 19, 526-535.
34. Zhang, H., Yang, B., Mu, X., et al. (2011). Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19, 1440-1448.